sj-docx-1-tpp-10.1177_20451253221135363 – Supplemental material for Classic psychedelics, health behavior, and physical health

Supplemental material, sj-docx-1-tpp-10.1177_20451253221135363 for Classic psychedelics, health behavior, and physical health by Otto Simonsson, Peter S. Hendricks, Richard Chambers, Walter Osika and Simon B. Goldberg in Therapeutic Advances in Psychopharmacology</p

What is the relationship between self-reported aberrant driving behaviors, mindfulness, and self-reported crashes and infringements?

<p><b>Objectives</b>: This study investigated the relationship between self-reported aberrant driving behaviors, mindfulness, and self-reported crashes and infringements.</p> <p><b>Methods</b>: Three hundred and eighteen participants (M = 46.0 years, SD = 13.7 years; female: 81.8%) completed an online survey that assessed aberrant driving behaviors, mindfulness (including regular mindfulness meditation [MM]), and self-reported crashes and infringements during the past 2 years. Structural equation modeling (SEM) was used to examine the relationship between self-reported aberrant driving behaviors and mindfulness simultaneously, as well as with participants' age and estimated kilometers driven over the past year.</p> <p><b>Results</b>: The results of the SEM showed that mindfulness was negatively related to each self-reported aberrant driving behavior, with the strongest relationships being between mindfulness and driving-related lapses (−0.58) and errors (−0.46). Participants who practice MM had significantly fewer crashes in the past 2 years and reported significantly fewer driving-related violations and lapses compared to participants who did not practice MM (crashes: 9.3% vs. 18.8%, <i>P</i> < .05; violations: M = 6.66 [SD = 3.44] vs. M = 7.68 [SD = 4.53], <i>P</i> < .05; errors: M = 5.17 [SD = 3.44] vs. M = 6.19 [SD = 4.12], <i>P</i> < .05).</p> <p><b>Conclusions</b>: More research is needed to understand whether MM results in more mindful and attentive drivers or whether individuals who practice MM may have other traits or behaviors that are linked to improved safety.</p

Mean per-patient healthcare costs for patients on increasing lines of treatment in US [63] and Europe [54].

<p>Mean per-patient healthcare costs for patients on increasing lines of treatment in US [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B63" target="_blank">63</a>] and Europe [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B54" target="_blank">54</a>].</p

US total healthcare costs of patients with HIV.

<p>Note: Right axis: mean per patient costs in 2000 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B57" target="_blank">57</a>] and 2006 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B58" target="_blank">58</a>]; Left axis: proportion of total healthcare costs due to hospitalizations and ARV drugs.</p

Reported prevalence of 1^st-generation NNRTI resistance in the US and European countries among treatment-naïve patients.

<p>Note: Solid and dotted lines indicate trend lines for Europe and US, respectively. References available from the author.</p

NNRTI and other class resistance in treatment-naïve patients in North America and Western Europe [12,13].

<p>NNRTI and other class resistance in treatment-naïve patients in North America and Western Europe [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B12" target="_blank">12</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B13" target="_blank">13</a>].</p

Additional file 1 of Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19

Additional file 1: Table S1. Reasons for Exclusion From the Study. ICD-10 International Classification of Diseases, 10th Revision, LTCF long-term care facility, SNF skilled nursing facility. aThere is no accurate date of death available, only month and year of death, so it was approximated to the last day of the month

Mean monthly per patient healthcare costs of US patients on ART from 1996 to 1998 [65].

<p>Mean monthly per patient healthcare costs of US patients on ART from 1996 to 1998 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072784#B65" target="_blank">65</a>].</p

Proportion of total cost by component and treatment line in the Newly Treated Cohort.

<p>ARV, antiretroviral; ER, emergency room.</p

Kaplan-Meier estimate of time to first treatment switch.

<p>Kaplan-Meier estimate of time to first treatment switch.</p